All In Biotech

Drug Trial Radar · NCT07172516

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 8, 2025

Primary completion

Jun 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Xenon Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).

Conditions

  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder

Interventions

  • AzetukalnerDrug

    Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks

  • PlaceboDrug

    Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.Time frame: Baseline to Week 6

Locations

44 sites in 4 countries. Site status is shown where the registry gives one.

  • Noble Clinical Research

    Tucson, Arizona

  • Woodland International Research Group

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • Clinical Innovations Inc

    Bellflower, California

  • ProScience Research Group

    Culver City, California

  • ATP Clinical Research

    Orange, California

  • NRC Research Institute

    Orange, California

  • Clinical Innovations Inc

    Riverside, California

  • Sunwise Clinical Research

    Walnut Creek, California

  • PharmaSouth Research, LLC

    Coral Gables, Florida

  • Sarkis Clinical Research

    Gainesville, Florida

  • Clinical Neuroscience Solutions, LLC

    Jacksonville, Florida

  • Central Miami Medical Institute

    Miami, Florida

  • Clinical Neuroscience Solutions, LLC

    Orlando, Florida

  • Synexus Clinical Research, Inc.

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • CenExel iResearch

    Decatur, Georgia

  • Denali Health Atlanta, LLC

    Stone Mountain, Georgia

  • Revival Research Institute

    Elgin, Illinois

  • Advanced Quality Medical Research

    Orland Park, Illinois

  • Psychiatric Care and Research Center

    O'Fallon, Missouri

  • Redbird Clinical Research, LLC

    Las Vegas, Nevada

  • Lumina Clinical Research Center

    Cherry Hill, New Jersey

  • Bio Behavioral Health

    Toms River, New Jersey

  • Integrative Clinical Trials LLC

    Brooklyn, New York

  • Neurobehavioral Research Inc

    Cedarhurst, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • DelRicht Research

    Charlotte, North Carolina

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania

  • Clinical Neuroscience Solutions, LLC

    Memphis, Tennessee

  • Elevate Synapsis, LLC

    Atascocita, Texas

  • Memorial Hermann Village

    Houston, Texas

  • Grayline Research Center

    Wichita Falls, Texas

  • Core Clinical Research

    Everett, Washington

  • Multiprofile Hospital for Active Treatment "Dr. Hristo Stambolski"

    Kazanlak, Bulgaria

  • State Psychiatric Hospital Lovech

    Lovech, Bulgaria

  • Saint Naum Medical Center

    Sofia, Bulgaria

  • Diagnostic and Consulting Center XI Sofia

    Sofia, Bulgaria

  • Diagnostics-Consultative Center Mladost M Varna OOD

    Varna, Bulgaria

  • Universitätsklinikum Carl Gustav Carus, TU Dresden - Klinik und Poliklinik für Psychiatrie

    Dresden, Germany

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.